AMETEK Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all proposals, including director elections and executive compensation. Record financial results were reported for 2025 and Q1 2026, and a major acquisition of Indicor's instrumentation group was announced, expected to close in late 2026.
-
A $5B acquisition of 10 mission-critical industrial technology businesses is expected to deliver strong cost synergies, premium margins, and recurring revenue, with efficient integration and no major regulatory hurdles anticipated. The deal is accretive in year one and enhances long-term growth and diversification.
-
Q1 2026 saw double-digit sales and record orders, robust margin expansion, and strong cash flow, prompting a raised full-year outlook. Segment growth was broad-based, with notable strength in defense, medical, and automation, and a strategic acquisition announced to expand defense MRO capabilities.
Fiscal Year 2025
-
Delivered record Q4 and full-year results with double-digit growth in sales, orders, and profit, driven by strong performance across segments and successful acquisitions. 2026 guidance calls for continued sales and EPS growth, robust cash flow, and ongoing margin expansion.
-
Q3 2025 saw record sales, orders, and earnings, with double-digit growth across key metrics and robust margin expansion. Full-year guidance was raised, driven by strong segment performance, successful acquisitions, and positive market trends, despite ongoing trade uncertainties.
-
Record Q2 sales and EBITDA, with strong margin and earnings growth, led to raised full-year guidance. FARO Technologies acquisition enhances digital reality offerings, while robust cash flow and a strong M&A pipeline support ongoing strategic investments.
-
Q1 2025 saw strong margin expansion, robust free cash flow, and EPS above guidance, despite flat sales and ongoing trade/tariff uncertainties. Orders and backlog remain near record levels, with full-year EPS and sales guidance reaffirmed.
-
Management outlined a balanced growth strategy combining organic initiatives and acquisitions, with a focus on high returns and operational excellence. End markets remain diverse, with aerospace/defense and medtech leading growth, while order momentum and backlog support future sales. M&A remains the top priority for capital deployment.
Fiscal Year 2024
-
Delivered record Q4 and full-year results with strong margins, cash flow, and EPS growth. 2025 guidance calls for low single-digit sales growth and 3–5% EPS increase, with robust capital deployment and a strong M&A pipeline.
-
Q3 saw strong results with EPS above guidance, robust margins, and record free cash flow. Orders and backlog grew, acquisitions expanded capabilities, and full-year EPS guidance was raised. Destocking and project delays persist, but positive order trends and a strong balance sheet support long-term growth.
-
Q2 saw strong operating results and margin expansion despite ongoing OEM destocking and cautious customer spending, prompting a slight reduction in full-year guidance. Segment performance was mixed, with EIG margins above 30% and Paragon Medical impacted by inventory normalization. Free cash flow and acquisition capacity remain robust.